Multiple myeloma: characteristics of long-term survivors

  • Hsieh RW & al.
  • Cancer
  • 28/06/2019

  • David Reilly
  • Univadis Clinical Summaries
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • In a population-based study of patients with multiple myeloma (MM), long-term survival (LTS) was associated with factors including sociodemographic advantages, lack of comorbidities, upfront stem cell transplantation (SCT), and high patient volume at treatment facility.

Why this matters

  • Data regarding LTS in patients with MM are scarce.

Study design

  • Population-based study to identify patient characteristics in long-term survivors of MM.
  • Data source: National Cancer Data Base (NCDB) years 2004-2006.
  • Funding: None disclosed.

Key results

  • 26,986 patients were identified from the NCDB; median OS=2.74 (95% CI, 2.68-2.80) years.
  • Patients were grouped according to median OS:
    • Group 1 (
    • Group 2 (2.74-5.48 years): n=5079.
    • Group 3 (5.48-8.22 years): n=3456.
    • Group 4 (≥8.22 years): n=4406.
  • In multivariate analysis, factors significantly associated with survival of ≥8.22 years vs
  • Upfront SCT: Adjusted OR (aOR)=0.48 (95% CI, 0.43-0.53); P<.001.>
  • Treatment at high-volume facility (>30 vs
  • Insured vs uninsured status: aOR=0.57 (95% CI, 0.45-0.71); P<.001.>
  • Charlson Comorbidity Index 0 vs ≥2: aOR=0.30 (95% CI, 0.24-0.37); P<.001.>

Limitations

  • NCDB data did not include tumor stage, cytogenetics.